Vai al contenuto principale della pagina
Autore: |
Leong James
![]() |
Titolo: |
Benefit-Risk Assessment of Medicines : The Development and Application of a Universal Framework for Decision-Making and Effective Communication / / by James Leong, Sam Salek, Stuart Walker
![]() |
Pubblicazione: | Cham : , : Springer International Publishing : , : Imprint : Adis, , 2015 |
Edizione: | 1st ed. 2015. |
Descrizione fisica: | 1 online resource (326 p.) |
Disciplina: | 306 |
353998 | |
610 | |
Soggetto topico: | Pharmacy |
Medical research | |
Drug Safety and Pharmacovigilance | |
Quality of Life Research | |
Persona (resp. second.): | SalekSam |
WalkerStuart | |
Note generali: | Description based upon print version of record. |
Nota di bibliografia: | Includes bibliographical references. |
Nota di contenuto: | Prologue -- Preface -- Overview -- Approaches to utilising decision-making framework -- Benefit-risk assessment of medicines by pharmaceutical companies and regulatory authorities -- Development of a universal benefit-risk framework and template -- Implementation of the benefit-risk assessment template by mature agencies -- Implementation of the benefit- risk summary template by a maturing agency: A case study -- Communicating benefit-risk decisions by US FDA, EMA, TGA and Health Canada -- Conclusions and future directions -- References. |
Sommario/riassunto: | This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox. Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view to developing a structured, systematic, standardized approach. Examining the evaluation of such an approach by several mature regulatory authorities ensures that the reader gains a unique insight into the ongoing debate in this area. The field of benefit-risk assessment continues to evolve at a rapid pace due to political and societal pressure, as is reflected in the recent FDA PUDFA agreement as well as in the EMA 2015 Roadmap. Rather than provide a comprehensive snap-shot of this constantly changing environment, this book evaluates selected current approaches to benefit-risk assessment. The strengths and weaknesses of publicly available documents in communicating benefit-risk decisions to stakeholders are reviewed, and these evaluations are used to inform development of a prospective framework that could be used to harmonise procedures globally. |
Titolo autorizzato: | Benefit-Risk Assessment of Medicines ![]() |
ISBN: | 3-319-15805-8 |
Formato: | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione: | Inglese |
Record Nr.: | 9910300234003321 |
Lo trovi qui: | Univ. Federico II |
Opac: | Controlla la disponibilità qui |